147 related articles for article (PubMed ID: 21439018)
21. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
[No Abstract] [Full Text] [Related]
22. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
23. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
24. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
25. Advances in drug development. BRAF validation in melanoma.
Flaherty K
Clin Adv Hematol Oncol; 2010 Jan; 8(1):31-4. PubMed ID: 20351680
[No Abstract] [Full Text] [Related]
26. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
[No Abstract] [Full Text] [Related]
27. Effectively targeting BRAF in melanoma: a formidable challenge.
Fecher LA; Amaravadi R; Schuchter LM
Pigment Cell Melanoma Res; 2008 Aug; 21(4):410-1. PubMed ID: 18710372
[No Abstract] [Full Text] [Related]
28. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
Postow MA
Clin Adv Hematol Oncol; 2018 May; 16(5):353-355. PubMed ID: 29851931
[No Abstract] [Full Text] [Related]
29. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
31. Re: Determinants of BRAF mutations in primary melanomas.
Purdue MP
J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
[No Abstract] [Full Text] [Related]
32. Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
Seishima M; Mizutani Y; Shibuya Y; Arakawa C; Yoshida R; Ogata T
Br J Dermatol; 2007 Dec; 157(6):1297-9. PubMed ID: 17927788
[No Abstract] [Full Text] [Related]
33. [New treatments for metastatic melanoma: a first hope].
Robert C; Mateus C
Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
[No Abstract] [Full Text] [Related]
34. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-ScarrĂ G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
[TBL] [Abstract][Full Text] [Related]
35. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
36. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
37. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
39. Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
[No Abstract] [Full Text] [Related]
40. [Gene abnormalities in melanoma and signal transduction antagonists].
Takada M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]